StockNews.com initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biopharmaceutical company's stock.

Separately, JPMorgan Chase & Co. cut shares of Clovis Oncology from a neutral rating to an underweight rating in a research note on Wednesday, November 9th.

Clovis Oncology Price Performance

The stock has a 50 day moving average of $0.52 and a 200 day moving average of $1.13. The firm has a market cap of $11.60 million, a PE ratio of -0.04 and a beta of 0.24. Clovis Oncology has a 12 month low of $0.08 and a 12 month high of $3.32.

Hedge Funds Weigh In On Clovis Oncology

Institutional investors have recently bought and sold shares of the business. First Republic Investment Management Inc. purchased a new position in Clovis Oncology during the 1st quarter worth approximately $27,000. Mirabella Financial Services LLP purchased a new position in shares of Clovis Oncology during the 1st quarter valued at approximately $36,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Clovis Oncology during the 1st quarter valued at approximately $40,000. Objective Capital Management LLC purchased a new position in shares of Clovis Oncology during the 2nd quarter valued at approximately $44,000. Finally, Bank of Montreal Can purchased a new position in shares of Clovis Oncology during the 1st quarter valued at approximately $48,000. 24.53% of the stock is owned by hedge funds and other institutional investors.

Clovis Oncology Company Profile

(Get Rating)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Articles

• Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
• Should You Warm up to Generac Stock for the Winter?
• Is Kintara Therapeutics A Hidden Gem?
• 3 High-Yield Dividend Stocks to Hold for the Long Haul
• Cal-Maine Posts Record Quarter, Remain CALM Income Investors
• Tesla Stock: What the Bulls and the Bears Are Getting Wrong

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.